Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

GE Spins Off Healthcare As Part Of Major Reorganization

Executive Summary

GE Healthcare will become a standalone company, distinct from GE, as the conglomerate focuses on its aviation, power, and renewable energy businesses, the company announced June 26. Current GE Healthcare CEO Kieran Murphy will continue to lead the business, which will maintain the GE Healthcare brand. GE plans to monetize 20% and distribute the remaining 80% of GE Healthcare to shareholders tax-free.

You may also be interested in...



GE Deals Biopharma Biz To Danaher For $21.4Bn; Planned Healthcare IPO Probably Won't Happen

The proposed IPO for GE's healthcare business could be off the table, CEO Lawrence Culp said as GE announced plans to sell its biopharma business to Danaher for $21.4bn. The deal will provide the conglomerate with a much needed cash injection to handle its rising debts.

GE Healthcare Spinoff On Track Despite Leadership Change

GE is replacing John Flannery as chairman and CEO with H. Lawrence Culp, formerly the chief of Danaher. But the change in leadership will not alter the company's previously announced plan to spin off GE Healthcare as a stand-alone business and make some other structural changes, the company says.

Device/Diagnostics Quarterly Dealmaking Statistics, Q2 2018

Second quarter device financing totaled $3.4 billion, less than half of the Q1 aggregate. Conversely, the $10.6 billion in device M&As was a 58% upsurge over the previous quarter. Like the device trends, total Q2 diagnostics financings (at $959 million) showed a 36% decline from Q1, while the $4.8 billion in M&A volume exhibited a significant increase over the previous quarter.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

MT122888

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel